Seat­tle Ge­net­ics gets ready to launch its sec­ond ADC af­ter scor­ing blad­der can­cer OK with part­ner Astel­las

Seat­tle Ge­net­ics and Astel­las have scored a tru­ly ac­cel­er­at­ed ap­proval to de­ploy their armed an­ti­body in sec­ond-line urothe­lial can­cer, adding an­oth­er promi­nent drug to the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER